DV
Dividend Vision

TNGX — Tango Therapeutics, Inc.

Tango Therapeutics, Inc. (TNGX)

Total return is 150.2% over the past 5.9 years, 6.1 points ahead of SPY at 144.1%. Its deepest 1-year drawdown was 29.2%.

TNGX is a single-stock equity holding in Tango Therapeutics, a biotechnology company focused on cancer research and drug development. The fund does not currently distribute dividends, making it unsuitable for income-focused investors seeking regular cash distributions. This holding appeals primarily to growth-oriented investors interested in exposure to the biotechnology sector and companies developing innovative cancer therapeutics.

TNGX key facts

Asset type
Stock
Asset class
Equity
Inception date
09/03/2020
Distribution frequency
None
Last close
$25.60
Market cap
$4,316,425,728
Average volume
1439388.0
Beta
1.152
Payout ratio
0.0
Forward P/E
0.0
EPS
$-0.84